Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880956 | 0.89 | NR1I2 (0.49) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL881020 | 0.89 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL880962 | 0.89 | NR1I2 (0.46) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL880943 | 0.87 | KCNH2 (0.56) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL881009 | 0.86 | KCNH2 (0.49) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10186911 | 0.84 | KCNH2 (0.52) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL881037 | 0.84 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10186017 | 0.84 | KCNH2 (0.52) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL881035 | 0.84 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL881008 | 0.84 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178878-B1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| US-7642251-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642251-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009023487-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090042860-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090042860-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042860-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885KCNH2 3808/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.